Zoledronic acid for the treatment of bone Metastases in patients with breast cancer and other solid tumors

被引：37
|
作者：
Lacerna, L [1 ]
Hohneker, J [1 ]
机构：
[1] Novartis Pharmaceut, Med Affairs, E Hanover, NJ 07936 USA
来源：
SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2003.08.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：150 / 160
页数：11
相关论文
共 50 条
  • [41] NTX and VEGF in cancer patients with bone metastases treated with zoledronic acid
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    [J]. EJC SUPPLEMENTS, 2010, 8 (05): : 23 - 23
  • [42] The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer
    Brown, JE
    Cook, RJ
    Major, P
    Lipton, A
    Lee, KA
    Zheng, M
    Hei, YJ
    Coleman, RE
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (09) : 1596 - 1596
  • [43] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Murat Dincer
    Kadri Altundag
    Hakan Harputluoglu
    Sercan Aksoy
    Mustafa Cengiz
    Ibrahim Gullu
    [J]. Medical Oncology, 2008, 25 : 356 - 359
  • [44] Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases
    Niikura, Naoki
    Liu, Jun
    Hayashi, Naoki
    Palla, Shana L.
    Tokuda, Yutaka
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    Theriault, Richard L.
    [J]. CANCER, 2012, 118 (08) : 2039 - 2047
  • [45] Zoledronic acid is being investigated for the prevention of bone metastases in patients with early-stage breast cancer
    Coleman, R
    Gralow, J
    Bell, R
    Lipton, A
    [J]. BONE, 2004, 34 : S85 - S85
  • [46] Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
    Stopeck, Alison T.
    Lipton, Allan
    Body, Jean-Jacques
    Steger, Guenther G.
    Tonkin, Katia
    de Boer, Richard H.
    Lichinitser, Mikhail
    Fujiwara, Yasuhiro
    Yardley, Denise A.
    Viniegra, Maria
    Fan, Michelle
    Jiang, Qi
    Dansey, Roger
    Jun, Susie
    Braun, Ada
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (35) : 5132 - 5139
  • [47] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Altundag, M. K.
    Dincer, M.
    Harputluoglu, H.
    Aksoy, S.
    Ozisik, Y.
    Guler, N.
    Tekuzman, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Dincer, Murat
    Altundag, Kadri
    Harputluoglu, Hakan
    Aksoy, Sercan
    Cengiz, Mustafa
    Gullu, Ibrahim
    [J]. MEDICAL ONCOLOGY, 2008, 25 (03) : 356 - 359
  • [49] Quality of Life Assessment in Taiwanese Patients with Bone Metastases from Breast Cancer Receiving Zoledronic Acid
    Chao, Ta-Chung
    Chen, Dar-Ren
    Chao, Tsu-Yi
    Chen, Shin-Cheh
    Yeh, Dah-Cherng
    Wang, Hwei-Chung
    Huang, Wen-Tsung
    Rau, Kun-Ming
    Chang, King-Jen
    Yang, Tsen-Long
    Lee, Kuan-Der
    Tai, Cheng-Jeng
    Tseng, Ling-Ming
    Hou, Ming-Feng
    [J]. ANTICANCER RESEARCH, 2013, 33 (12) : 5543 - 5547
  • [50] Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer.
    Mercatali, L.
    Ibrahim, T.
    Sacanna, E.
    Ricci, R.
    Scarpi, E.
    Fabbri, F.
    Serra, P.
    Tison, C.
    Amadori, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345